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Abstract
Introduction The purpose of this study was to investigate the
prevalence of cyclic citrullinated peptide antibodies (anti-CCP)
in patients with primary Sjögren syndrome (pSS) and its
correlation with clinical and laboratory data.
Methods We analysed the clinical and serological data of 155
consecutive patients with pSS. Among these, 14 were excluded
due to fulfillment of American College of Rheumatology criteria
for rheumatoid arthritis (RA). So, 141 patients (27 males and
114 females; mean age 48 years, range 39 to 60) were clinically
assessed for the presence of synovitis (objective swelling of one
or more joints) and extra-glandular involvement. The anti-CCP
antibodies were tested using a commercially available second-
generation enzyme-linked immunosorbent assay. IgM
rheumatoid factor (RF) was determined by nephelometry.
Results Fourteen patients (9.9%) had moderate to high levels
of anti-CCP, and 94 (66.7%) were positive for RF. Eighty-one
(57.4%) showed extra-glandular involvement, and 44 (31.2%)
had synovitis without any radiographic sign of erosion. There
was a close correlation between the presence of anti-CCP and
synovitis (P < 0.001) but no association between anti-CCP and
extra-glandular involvement (P = 0.77). Multivariate analysis
confirmed the association between anti-CCP and an increased
prevalence of synovitis (prevalence odds ratio for positive versus
negative anti-CCP status 7.611, 95% confidence interval 1.475
to 74.870; P = 0.010).
Conclusion Only a minority of patients with pSS are anti-CCP-
positive, which seems to be closely associated with the
prevalence of synovitis. Anti-CCP positivity in patients with pSS
therefore may be a predictor of future progress to RA or an
expression of the inflammatory process of synovial tissue.
Introduction
Primary Sjögren syndrome (pSS) is a chronic, slowly progres-
sive, inflammatory, autoimmune disease that is characterised
by lymphocytic infiltration of the exocrine glands (which
reduces or eliminates glandular secretion) and marked B-lym-
phocytic cell hyper-reactivity, which initially is manifested by a
variety of serum autoantibodies, including those against Ro
(SSA) and La (SSB), and rheumatoid factor (RF) [1-4].
Most patients with pSS present only with keratoconjunctivitis
sicca and xerostomia, but approximately 40% develop extra-
glandular musculoskeletal manifestations; lung, kidney, and
skin involvement; vasculitis; neuropathy; and lymphoma [1,2].
The most common are arthralgia and an intermittent non-ero-
sive polyarthropathy affecting mainly the small joints, which
means that the picture may mimic that of rheumatoid arthritis
(RA), particularly as 50% to 80% of cases are RF-positive
[4,5]. However, the fact that tests for cyclic citrullinated pep-
tide antibodies (anti-CCP) usually are negative may help to dif-
ferentiate the two conditions. Anti-CCP antibodies, which
were first described in 1998, were found to be highly specific
in the diagnosis of RA (95%) and only slightly less sensitivePage 1 of 6
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ation of anti-CCP antibodies have a sensitivity of 80% and a
specificity of 98%. Follow-up studies of patients with early RA
have demonstrated that anti-CCP antibodies independently
predict the development of erosions [8,9], but Goëb and col-
leagues [10] found anti-CCP autoantibodies in only 4% of
137 women and 16% of 11 men with pSS.
Gottenberg and colleagues [11] studied a cohort of 134
patients with pSS and found that 7.5% of the serum samples
were positive for anti-CCP antibodies and 5.2% were positive
for anti-keratin antibodies (AKAs) without any radiographic evi-
dence of erosion after a long follow-up. They suggested that
the anti-CCP-positive patients, who may be prone to develop-
ing RA, require cautious clinical and radiographic follow-up.
The aims of this study were to verify the prevalence of anti-
CCP antibodies in patients with pSS and to investigate any
associations with their clinical and laboratory characteristics.
Materials and methods
Patients
The study involved 155 consecutive SS patients who were
evaluated at three tertiary rheumatologic referral centres and
who fulfilled the American-European Consensus Group diag-
nostic criteria [12]. Fourteen patients with SS fulfilling the
American College of Rheumatology (ACR) criteria for RA and/
or presenting at least one joint erosion [13] were excluded;
141 patients (114 women and 27 men; mean age 48 years,
range 39 to 60; mean disease duration 0.98 ± 6.12 years)
were considered for the present study. ACR criteria were con-
sidered to be fulfilled if at least four criteria were present simul-
taneously for at least 6 weeks. All of the study subjects had
their medical history recorded and underwent a clinical
assessment, including 'synovitis' (defined as objective swell-
ing of one or more joints in the absence of erosions) and extra-
glandular involvement, erythrocyte sedimentation rate (ESR),
C-reactive protein, RF, and anti-CCP, anti-extractable nuclear
antigen (ENA), and antinuclear antibodies (ANAs). Hand and
foot radiographs were also evaluated. Written informed con-
sent was obtained from the patients before their inclusion in
the study, which was approved by the ethics committees of
the participating centres. All of the patients with synovitis and
anti-CCP antibodies were re-evaluated by an experienced
rheumatologist to definitively exclude a diagnosis of RA
according to ACR criteria. To be classified as having RA,
patients had to have met four criteria simultaneously for at
least 6 weeks by the time of the evaluation or in the past.
Detection of anti-cyclic citrullinated peptide antibodies
Anti-CCP antibodies were tested using a commercially availa-
ble second-generation enzyme-linked immunosorbent assay
(ELISA) kit (Axis-Shield, Dundee, UK) as previously described
[14]. The serum samples were evaluated in triplicate, with the
upper normal limit of 5 IU/mL being assumed in accordance
with the manufacturer's recommendations. Plates from the
same batch (#470094) were used in order to avoid any plate-
to-plate variations in anti-CCP measurements. Inter- and intra-
assay variability was less than 9%.
Detection of rheumatoid factor
IgM RF was measured by means of immunonephelometry
using the quantitative N Latex RF system (Dade Behring, now
part of Siemens AG, Munich, Germany). Concentrations of
greater than 15 IU/mL were considered positive.
Detection of antinuclear and anti-extractable nuclear 
antigen antibodies
ANAs were tested by means of standard indirect immunofluo-
rescence, as previously described [14], using a BX 51 Olym-
pus fluorescence microscope (Olympus Optical Co.,
Hamburg, Germany) at ×40 power. ENA antibodies were eval-
uated in triplicate using commercially available ELISA kits
(Axis-Shield) according to the manufacturer's recommenda-
tions. The following individual ENA specificities were investi-
gated: Sm, RNP, SSA (Ro), SSB (La), Scl-70, and Jo1.
Radiographic assessment
Radiographs of the hands and feet were evaluated at the time
of the anti-CCP analysis. Patients with at least one erosion
were excluded from the study.
Statistical analysis
The data were statistically analysed by means of R software,
version 2.5 [15], using the Wilcoxon non-parametric rank sum
test for continuous variables, and the Fisher exact or Pearson
chi-square test with Yates' continuity correction for discrete
variables. All of the analyses were two-tailed. P values of less
than 0.05 were considered as indicating statistical signifi-
cance. The variables found to be significantly associated with
the prevalence of anti-CCP positivity at the univariate level
were examined in a logistic regression model using exact infer-
ence (LogXact version 7; Cytel Inc., Cambridge, MA, USA).
The prevalence odds ratio (OR) was used as the effect meas-
ure in this prevalence study [16].
Results
Fourteen (9.9%) of the patients with pSS had moderate to
high levels of anti-CCP antibody, and 94 (66.7%) were RF-
positive, 134 (95%) ANA-positive, 115 (81.6%) SSA-positive,
and 55 (39%) SSB-positive (Table 1). The mean value for anti-
CCP antibodies was 46 IU/mL (28 to 78), with a normal range
(as defined by the manufacturer) of less than 5 IU/mL. None of
the 14 patients fulfilled the ACR criteria for RA. The focus
score at lip biopsy was greater than 1 in 94 patients (67.1%).
Extra-glandular involvement was found in 81 patients (57.4%)
(Table 2), and synovitis was found in 44 (31.2%) without any
radiographic evidence of erosions (Table 1).Page 2 of 6
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There were no correlations between RF titres and synovitis (P
= 0.65), extra-glandular involvement (P = 0.85), laboratory
parameters, or focus scores, and there were no significant dif-
ferences between the RF-positive and RF-negative patients in
terms of age (P = 0.26) or disease duration (P = 0.55).
Anti-CCP-positive primary Sjögren syndrome patients
There was a close relationship between anti-CCP positivity
and synovitis (P < 0.001) but not between anti-CCP positivity
and other extra-glandular involvement (P = 0.77). There were
no significant differences between the anti-CCP-positive and
-negative patients in terms of age (P = 0.13), disease duration
(P = 0.41), mean ESR (P = 0.10), the presence of anti-SSA
(P = 0.29), anti-SSB (P = 0.78), or RF (P = 0.77) or a focus
score of greater than 1 (P = 0.77) (Table 3).
Multivariable analysis of synovitis
An exact logistic regression analysis was used to model the
effects of the presence of positive anti-CCP antibodies on the
prevalence of synovitis, adjusting for the potential covariates of
age, disease duration, gender, and anti-SSA and anti-SSB
antibodies. Age and disease duration were divided into quar-
tiles with the aim of simplifying the interpretation of the results
by comparing the oldest patients and those with the longest
disease duration. Anti-SSA and anti-SSB antibodies were
included in the model because they were found in 60% of the
patients and are associated with more frequent extra-glandular
manifestations [4,17]. As shown in Table 4, multivariate analy-
sis of the anti-CCP-positive patients, adjusted for age, gender,
disease duration, and anti-SSA and anti-SSB antibodies, con-
firmed the association with an increased prevalence of synovi-
tis (prevalence OR versus anti-CCP-negative patients =
7.611, 95% confidence interval [CI] 1.475 to 74.870; P =
0.010). None of the covariables included in the model was sta-
tistically significant except for anti-SSB antibodies, which
were of borderline significance (prevalence OR versus anti-
SSB-negative patients = 0.393, 95% CI 0.130 to 0.967; P =
0.084). Diagnostic procedures did not reveal any violations of
the model assumptions, and the test of the deviance did not
provide any evidence requiring the rejection of the null hypoth-
esis of goodness-of-fit (P > 0.23).
Table 1
Demographic and clinical features of 141 patients with primary Sjögren syndrome
Number Percentage
Females/Males 114/27 80.9/19.1
Age (range), years 48 (39–60)
Median disease duration (IQR), years 2.49 (0.98–6.12)
Synovitis (objective swelling) 44 31.2
Extra-glandular involvement (skin, lung, kidney, or vasculitis) 81 57.4
Median erythrocyte sedimentation rate (IQR), mm/1st hour 27 (17–38)
Median C-reactive protein (IQR), mg/dL 0.57 (0.31–0.9)
Rheumatoid factor 94 66.7
Anti-CCP antibodies 14 9.9
Anti-nuclear antibodies 134 95
Anti-La (SSB) antibodies 55 39.1
Anti-Ro (SSA) antibodies 115 81.6
Focus score of greater than 1 94 67.1
Demographic characteristics and continuous data are expressed as median (interquartile range, IQR). Categorical data are expressed as absolute 
frequency and percentage. Anti-CCP, cyclic citrullinated peptide antibody.
Table 2
Extra-glandular involvement in 141 patients with primary 
Sjögren syndrome subdivided for the specific manifestations
Number Percentage
Raynaud phenomenon 81 57
Lymphadenopathy 18 13
Cutaneous vasculitis 9 6
Lung involvement 18 13
Kidney involvement 6 4
Liver involvement 7 5
Peripheral neuropathy 15 11
Myositis 3 2
Lymphoma 0 0Page 3 of 6
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Musculoskeletal manifestations such as fatigue, myalgia,
arthralgia, an intermittent non-erosive polyarthropathy affect-
ing mainly the small joints, and usually mild synovitis are com-
mon in patients with pSS and may mimic RA, particularly in the
presence of RF [2,3,18], although the fact that tests for anti-
CCP antibodies usually are negative may help to differentiate
the two conditions [19,20].
We found slightly high anti-CCP levels in 14 of our 141
patients with pSS (9.9%). Some studies have found that anti-
CCP antibodies are an independent factor predicting the
development of erosions in patients with RA [8,9], but none of
our 44 pSS patients with synovitis (31.2%) showed any radi-
ographic sign of erosions. After a long follow-up, Gottenberg
and colleagues [11] found that 80 out of 134 pSS patients
with no radiographic evidence of erosions (59%) were positive
for IgM RF, 10 (7.5%) for anti-CCP, 7 (5.2%) for AKA, and 5
(3.7%) for both anti-CCP and AKA.
We also found no significant differences between our anti-
CCP-positive and -negative patients in terms of demographic
factors or extra-glandular manifestations. However, the pres-
ence of synovitis in pSS patients did seem to be closely asso-
ciated with the presence of anti-CCP antibodies as the odds
of having synovitis were 1.475 times greater in our anti-CCP-
positive patients, regardless of the other covariables in the
model. There were no other significant associations with clini-
cal or laboratory parameters between the anti-CCP-positive
and -negative patients.
In addition, anti-SSB positivity was weakly and inversely asso-
ciated with the prevalence of synovitis. Antibodies to the Ro/
SSA and La/SSB ribonucleoprotein particles usually are
found in the serum of pSS patients and are associated with a
longer disease duration, more frequent non-exocrine manifes-
tations, and more intense lymphocytic infiltration of the minor
salivary glands [21]. The prevalence of anti-SSB is higher in
pSS, but in our patient cohort it was also inversely related to
the presence of synovitis.
The possibility that our anti-CCP patients represent a sub-
group of patients with RA and secondary SS was ruled out by
excluding patients fulfilling ACR criteria at the beginning of the
study and re-evaluating all of the anti-CCP-positive patients. In
our study, we decided to be very stringent in the application of
ACR criteria, and we classify as RA those patients in whom
clinical symptoms (symmetrical arthritis, arthritis of the hands,
more than three groups of joints involved, and morning stiff-
ness) were simultaneously present at the moment of evalua-
tion or for at least 6 weeks in the past. In fact, even if we had
considered the possibility of a diagnosis of RA for symptoms
that were successive and not simultaneously present, none of
the 14 patients would have been classifiable as having RA
(data not shown).
Indeed, the possibility that patients with anti-CCP antibodies
may develop RA cannot be ruled out by the present study, and
it is possible that in the future anti-CCP will be interpreted as
an additional marker of definite RA. It should be noted, how-
ever, that anti-CCP antibodies are strictly associated with the
development of erosions in RA and that none of our patients
developed erosions after a mean follow-up of 2.4 years.
As a matter of fact, anti-CCP antibodies may also be observed
in a minority of patients with other systemic autoimmune dis-
eases. Takasaki and colleagues [22] detected anti-CCP anti-
bodies in patients with mixed connective tissue disease
(MCTD) (9%), systemic lupus erythematosus (14%), systemic
sclerosis (13%), polymyositis/dermatomyositis (14%), and SS
Table 3
Correlations with clinical and laboratory parameters of anti-CCP antibody-positive and -negative primary Sjögren syndrome 
patients
Anti-CCP-positive (n = 14) Anti-CCP-negative (n = 127) P value
Age (range), years 41 (34.5–52.2) 49 (39–60) 0.134
Disease duration, years 2.4 (1.40–7.5) 2.5 (0.98–5.2) 0.415
Synovitis, number (percentage) 12 (85.7) 32 (25.2) <0.001
Extra-glandular involvement, number (percentage) 9 (64.3) 72 (56.7) 0.777
Erythrocyte sedimentation rate (range), mm/1st hour 34 (24.25–45.5) 27 (16.5–38) 0.101
Rheumatoid factor, number (percentage) 10 (71.4) 84 (66.1) 0.774
Anti-nuclear antibodies, number (percentage) 13 (92.9) 121 (95.3) 0.527
Anti-La (SSB) antibodies, number (percentage) 10 (71.4) 105 (82.7) 0.291
Anti-Ro (SSA) antibodies, number (percentage) 6 (42.9) 49 (38.6) 0.779
Focus score of greater than 1, number (percentage) 9 (64.3) 85 (67.5) 0.773
Anti-CCP, cyclic citrullinated peptide antibody.Page 4 of 6
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connective tissue diseases (particularly MCTD) and so, as
inthe case of other autoimmune diseases, anti-CCP positivity
in pSS may be a marker of synovial tissue inflammation. The
results of our study suggest that the production of anti-CCP
antibodies may be less related to the pathogenesis of RA. It is
possible that marked B-lymphocyte hyper-reactivity (a charac-
teristic of pSS) may explain the presence of anti-CCP antibod-
ies, as usually is observed in the case of RF and anti-SSA and
anti-SSB antibodies [23].
Conclusion
Only a minority of patients with pSS are anti-CCP-positive, but
the prevalence of synovitis seems to be closely associated
with the presence of anti-CCP antibodies as multivariate anal-
ysis confirmed the association between anti-CCP positivity
and an increased prevalence of synovitis. However, the possi-
bility that patients with anti-CCP antibodies may develop RA
cannot be ruled out, particularly in patients with the concomi-
tant presence of IgM RF.
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